IAS 2103: Dolutegravir Beats Raltegravir for Treatment-experienced HIV Patients [VIDEO]
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 03 July 2013 00:00
- Written by Gregory Fowler
The once-daily HIV integrase inhibitor dolutegravir demonstrated better efficacy than twice-daily raltegravir (Isentress), with fewer study withdrawal due to virological failure and less drug resistance, according to data from the SAILING trial presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
IAS 2013: Reduced Efavirenz Dose Suppresses HIV as Well as Standard Dose
- Details
- Category: HIV Treatment
- Published on Wednesday, 03 July 2013 00:00
- Written by Liz Highleyman
Lowering the dosage of efavirenz (Sustiva) from 600 to 400 mg in an antiretroviral regimen did not compromise efficacy, and has the potential to substantially reduce treatment cost, according to data from the ENCORE1 study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
IAS 2013: AbbVie Interferon-Free Hepatitis C Combo Works Well with Reduced Ribavirin Dose
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 02 July 2013 00:00
- Written by Liz Highleyman
Hepatitis C patients who reduced their dose of ribavirin due to side effects nevertheless had a high likelihood of achieving sustained response when treated with an all-oral regimen containing 3 direct-acting antiviral agents, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
IAS 2013: Dolutegravir Superior to Raltegravir for Treatment-experienced People with HIV
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 03 July 2013 00:00
- Written by Liz Highleyman
The once-daily HIV integrase inhibitor dolutegravir demonstrated better efficacy than twice-daily raltegravir for previously treated people with HIV, with fewer study withdrawals due to virological failure and less emergent drug resistance, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. Results were published concurrently in the July 3, 2013, online edition of The Lancet.
IAS 2013: Experts Discuss Role of Drug Policy in HIV, Hepatitis, and TB Epidemics
- Details
- Category: People Who Inject Drugs
- Published on Tuesday, 02 July 2013 00:00
- Written by Liz Highleyman
International drug policy must shift from prohibition to public health in order to reduce harms to individuals and societies, including fueling the spread of HIV, hepatitis, and tuberculosis, experts from a range of disciplines agreed at 2 sessions held during the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
More Articles...
- IAS 2013: German Researchers Report Case of Functional Cure After Very Early HIV Treatment
- IAS 2013: Starting Treatment with CD4s Above 500 Reduces HIV Reservoir during Long-term Infection
- IAS 2013: Adolescents with HIV Face Challenges Transitioning to Adulthood [VIDEO]
- IAS 2013: New WHO Guidelines on HIV Treatment for Children Require Earlier Diagnosis
Web Design and Development by